Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 12, Issue 6, 1998, Pages 1409-1414

  Kolb, M ^a   Kirschner, J ^a   Riedel, W ^a   Wirtz, H ^a   Schmidt, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cyclophosphamide; Lung fibrosis; Pulse therapy

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT INFECTION; VITAL CAPACITY;

ADMINISTRATION, ORAL; ADULT; AGED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; VITAL CAPACITY;

EID: 0032424030     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12061409     Document Type: Article

References (28)

1. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801-809.
2. Meier-Sydow J, Weiss SM, Buhl R, Rust M, Raghu G. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15: 77-96.
3. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 127: 1-8.
4. Cherniack RM, Crystal RG, Kalica AR. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Respir Dis 1991; 143: 680-683.
5. Meyer KC, Raghu G. Perspectives and future advances on the diagnosis and treatment of idiopathic pulmonary fibrosis. In: Pulmonary Fibrosis. Lung Biology in Health and Disease, Vol. 80. New York, Marcel Dekker, 1995; pp. 837-871.
6. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.
7. Johnson MA, Kwan S, Snell JC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomized controlled trial comparing prednisone alone with phosphamide and low dose prednisone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
8. Baughman RP, Lower EE. Use of intermittent intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102: 1090-1094.
9. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 14: 291-296.
10. Cupps TR. Cyclophosphamide: to pulse or not to pulse? Am J Med 1990; 89: 399-402.
11. Austin HA, Kippel JH, Balon JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic fibrosing drugs. N Engl J Med 1986; 313: 614-619.
12. Haslam PL, Turton CWG, Lukoszek A, et al. Bronchoalveolar lavage cell counts in cryptogenic fibrosing alveolitis and their relations to therapy. Thorax 1980; 35: 328-339.
13. Mortenson RL, Panos RJ, King TE Jr. Idiopathic pulmonary fibrosis. In: Bone RC, ed. Pulmonary and Critical Care Medicine. Vol. M. St Louis, MO, Mosby Year Book, 1993; pp. 1-14.
14. Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989; 16: 1592-1596.
15. Weese WC, Levine BW, Kazemi H. Interstitial lung disease resistant to corticosteroid therapy: report of three cases treated with azathioprine or cyclophosphamide. Chest 1975; 67: 57-60.
16. Boulware DW, Makkena R. Monthly cyclophosphamide in lupus pneumonitis and myositis. J Rheumatol 1991; 18: 153.
17. Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA. Therapy for severe interstitial lung disease in systemis sclerosis. Arthritis Rheum 1994; 37: 1290-1296.
18. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low dose prednisone in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-844.
19. Valeri J, Radhakrishnan D, Estes D, et al. Intravenous pulse cyclopliosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-78.
20. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108: 305-310.
21. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103.
22. Van Oortegrem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1997; 7: 1950-1957.
23. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-599.
24. Turner-Warwick M, Haslam P. The value of serial bronchoalveolar lavages in assessing the clinical progress of patient with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135: 26-34.
25. Watters LC, Schwarz MI, Cherniak RM, et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696-704.
26. Panos RJ. Therapy and management of idiopathic pulmonary fibrosis. Compr Ther 1994; 20: 289-293.
27. Lynch JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155: 395-420.
28. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53.